Noroxymorphone

Noroxymorphone is an opioid^[1] which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of opioid antagonists such as naltrexone and others. It is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood–brain barrier into the central nervous system, and for this reason, has only minimal analgesic activity.^[2][3][1]

Dependence
liabilityHigh

Routes of
administrationIntravenous, intramuscular, subcutaneous, oral, rectal, intranasal

Drug classOpioid

Legal status

• US: Schedule II

Quick facts Clinical data, Dependenceliability ...

Noroxymorphone

Clinical data
Dependence liability	High
Routes of administration	Intravenous, intramuscular, subcutaneous, oral, rectal, intranasal
Drug class	Opioid
Legal status
Legal status	US: Schedule II
Identifiers
IUPAC name 7,8-Dihydro-14-hydroxynormorphinone
CAS Number	33522-95-1
PubChem CID	5497189
DrugBank	DBMET00424
ChemSpider	4593755
UNII	9NZ7111A9O
CompTox Dashboard (EPA)	DTXSID80955145
ECHA InfoCard	100.046.859
Chemical and physical data
Formula	C16H17NO4
Molar mass	287.315 g·mol−1
3D model (JSmol)	Interactive image
SMILES Oc1ccc2C[C@H]3NCC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O
InChI InChI=1S/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/m1/s1 Key:HLMSIZPQBSYUNL-IPOQPSJVSA-N

Close

In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637. In 2014, the DEA set annual aggregate manufacturing quotas of 17,500 kg for conversion and 1,262.5 kg for sale.^[4]